Format

Send to

Choose Destination
Crit Care Med. 2012 Jan;40(1):104-11. doi: 10.1097/CCM.0b013e31822e9d66.

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.

Author information

1
Service d'Hématologie Clinique et de Thérapie Cellulaire, AP-HP, Groupe Hospitalier Pitié-Salpétrière, UPMC Univ Paris 6, Paris, France.

Abstract

OBJECTIVE:

To assess the efficacy and safety of rituximab in adults responding poorly to standard treatment for severe autoimmune thrombotic thrombocytopenic purpura.

DESIGN:

Open-label prospective study. Outcomes in the survivors were compared to those of 53 historical survivors who were given therapeutic plasma exchange alone or with vincristine.

SETTING:

Hospitals belonging to the Reference Network for Thrombotic Microangiopathies in France.

PATIENTS:

Twenty-two adults with either no response or a disease exacerbation when treated with intensive therapeutic plasma exchange.

INTERVENTION:

Add-on rituximab therapy, four infusions over 15 days.

MEASUREMENTS AND MAIN RESULTS:

One patient died despite two rituximab infusions. In the rituximab-treated patients, the time to a durable remission was significantly shortened (p = .03), although the plasma volume required to achieve a durable remission was not significantly different compared to the controls. Platelet count recovery occurred within 35 days in all 21 survivors, compared to only 78% of the historical controls (p < .02). Of the rituximab-treated patients, none had a relapse within the first year but three relapsed later on. In patients treated with rituximab, a rapid and profound peripheral B-cell depletion was produced, lasting for 9 months and correlating with higher a disintegrin and metalloproteinase with thrombospondin-13 activity and lower anti-a disintegrin and metalloproteinase with thrombospondin-13 antibody titers. These differences were no longer significant after 12 months. No severe side effects occurred.

CONCLUSIONS:

Adults with severe thrombocytopenic purpura who responded poorly to therapeutic plasma exchange and who were treated with rituximab had shorter overall treatment duration and reduced 1-yr relapses than historical controls.

PMID:
21926591
DOI:
10.1097/CCM.0b013e31822e9d66
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center